title: The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension.
abstract: In recent years, the process of the programmed cell death has gained much interest because it has important pathophysiological consequences contributing to the deletion of unwanted cells in the vessel wall, loss of pulmonary smooth muscle cells and therefore in reversing the pulmonary pressure. For the reason that most patients with pulmonary hypertension present with limited reversibility with vasodilators, antiremodeling approach for treatment appears to be feasible. Induction or enhancement of vascular smooth muscle cells apoptosis may be targeted to develop novel therapeutic approaches for pulmonary vascular remodeling in patients with pulmonary hypertension. This review summarizes the current mechanisms, investigate the roles and provide novel insights into the potential therapeutic value of apoptosis in the pulmonary artery remodeling of pulmonary hypertension.
authors.affiliation: Huazhong University of Science and Technology, Tongji Medical College, Union Hospital, Department of Cardiovascular Surgery, Wuhan 430030, PR China. emin_cn@yahoo.com
authors.forename: Emin
authors.initials: E
authors.lastname: Gurbanov
authors.forename: Xiao
authors.initials: X
authors.lastname: Shiliang
mesh_terms: D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D003999:Dichloroacetic Acid / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000503:physiopathology*; D051034:Inhibitor of Apoptosis Proteins; D047908:Intracellular Signaling Peptides and Proteins / Q000627:therapeutic use; D008148:Lovastatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D048848:MAP Kinase Kinase Kinase 5 / Q000627:therapeutic use; D008869:Microtubule-Associated Proteins / Q000627:therapeutic use; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D009363:Neoplasm Proteins / Q000627:therapeutic use; D047495:PPAR gamma / Q000627:therapeutic use; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors; D017346:Protein Serine-Threonine Kinases / Q000627:therapeutic use; D011652:Pulmonary Circulation / Q000502:physiology; D043782:Receptor, Bradykinin B2 / Q000819:agonists; D019821:Simvastatin / Q000627:therapeutic use; D000077022:Survivin; D013927:Thrombosis / Q000503:physiopathology; D014661:Vasoconstriction / Q000502:physiology; D054460:rho-Associated Kinases
chemical_list: C107489:BIRC5 protein, human; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D051034:Inhibitor of Apoptosis Proteins; D047908:Intracellular Signaling Peptides and Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D047495:PPAR gamma; D043782:Receptor, Bradykinin B2; D000077022:Survivin; C012258:mevastatin; D008148:Lovastatin; D003999:Dichloroacetic Acid; D019821:Simvastatin; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases; D048848:MAP Kinase Kinase Kinase 5; D010196:Pancreatic Elastase